Opus Genetics expects cash runway to extend into 2029
IRD•Opus Genetics expects its cash to fund five clinical programs through multiple milestones into 2029, with four clinical data readouts expected in 2027 and BEST1 pivotal trial dosing scheduled to begin in the second half.
1. Cash and clinical milestones
Opus Genetics expects its current cash runway to extend into 2029, funding five clinical programs through multiple critical milestones. The company expects four clinical data readouts in 2027, and plans to begin dosing in its BEST1 pivotal trial in the second half.
